Fibrosis

From repair to scar

Every tissue knows how to heal. When skin is cut, liver is bruised, or lung is burned, a tightly choreographed program closes the breach: platelets and a fibrin clot plug the gap, inflammatory cells clear debris, blood vessels regrow, and fibroblasts migrate in to rebuild the structural scaffold. Those fibroblasts transiently become myofibroblasts — activated cells studded with alpha-smooth-muscle actin (α-SMA) stress fibers — that both secrete collagen and physically contract to pull wound edges together. In a normal wound this phase is brief. Once the defect is sealed, roughly 90 percent of the myofibroblasts die by apoptosis, surplus matrix is trimmed back by matrix metalloproteinases, and the tissue settles into a modest, mature scar.

Fibrosis is this same program run amok. When injury is not a single event but a chronic insult — hepatitis virus replicating in liver cells, silica dust lodged in alveoli, glucose-soaked capillaries in the kidney, mechanical overload on the heart — the repair signal never switches off. Myofibroblasts keep being recruited and refuse to die. They lay down layer after layer of dense, cross-linked extracellular matrix that does not patch the tissue so much as bury it. The functional cells — hepatocytes, pneumocytes, nephron tubules, cardiomyocytes — are progressively walled off, starved of blood supply, and lost. What remains is scar: tough, stiff, and inert.

The molecular engine: TGF-beta and the myofibroblast

At the center of nearly every fibrotic disease sits transforming growth factor beta (TGF-beta, principally the TGF-β1 isoform). It is stored in the matrix in a latent, inactive form bound to latency-associated peptide. Injury, inflammation, reactive oxygen species, and — critically — mechanical tension liberate active TGF-β1, which binds its receptor and drives the SMAD2/3 signaling cascade into the nucleus. There it switches on the genes for type I and type III collagen, fibronectin, connective-tissue growth factor, and α-SMA, while simultaneously inducing tissue inhibitors of metalloproteinases (TIMPs) that block the enzymes that would otherwise degrade matrix. The balance tips hard toward deposition.

The cell that executes this program is the myofibroblast. It does not have a single origin: in the liver it derives mainly from hepatic stellate cells that transdifferentiate from fat-storing quiescent cells; in the kidney from pericytes and resident interstitial fibroblasts; in the lung from resident fibroblasts and circulating fibrocytes; and some arise via epithelial-to-mesenchymal transition. Whatever its source, the activated myofibroblast is a contractile collagen factory. Its α-SMA stress fibers let it tug on the surrounding matrix, and that traction does two damaging things: it physically distorts tissue architecture, and it mechanically activates even more latent TGF-β1. The stiffer the scar becomes, the more it activates mechanosensors such as YAP/TAZ inside the fibroblasts, which respond by making still more collagen. This is the vicious feed-forward loop that turns a self-limiting repair into relentless, progressive fibrosis.

The numbers: stiffness, collagen, and lost function

The defining biochemical lesion of fibrosis is the wrong amount and kind of collagen. Healthy tissue carries a thin, organized matrix dominated by basement-membrane collagen (type IV) and fine type III fibers. Fibrotic tissue is flooded with thick, disorganized type I collagen fibrils that are then chemically cross-linked by lysyl oxidase — the same enzyme chemistry that turns hide into leather. In advanced cirrhosis, total hepatic collagen can rise several-fold above normal. That accumulation translates directly into mechanical stiffness, which is now measured routinely at the bedside.

Normal liver measures roughly 2 to 6 kilopascals (kPa) on transient elastography; significant fibrosis begins around 8 kPa, and established cirrhosis runs from 12 kPa to as high as 75 kPa — an order of magnitude stiffer than healthy tissue. In the lung, fibrosis is tracked functionally: forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLCO) fall as scar replaces alveolar surface, and a decline in FVC of more than 10 percent per year marks aggressive idiopathic pulmonary fibrosis with a median survival historically near 3 to 5 years from diagnosis. In the heart, replacement fibrosis after a myocardial infarction converts contractile muscle into akinetic scar; once more than a critical fraction of the ventricle is fibrotic, ejection fraction falls and the substrate for re-entrant arrhythmia is set.

Where fibrosis strikes

• Lung — pulmonary fibrosis. Idiopathic pulmonary fibrosis, pneumoconioses (silicosis, asbestosis), drug toxicity (bleomycin, amiodarone), and post-COVID fibrosis all thicken the alveolar wall, collapsing gas exchange and producing the characteristic "honeycomb" lung on CT.
• Liver — cirrhosis. Chronic hepatitis B and C, alcohol, and metabolic (fatty) liver disease drive hepatic stellate cells to wall hepatocytes into regenerative nodules, raising portal pressure and causing varices, ascites, and liver failure.
• Kidney — chronic kidney disease. Diabetes and hypertension produce glomerulosclerosis and tubulointerstitial fibrosis; the degree of interstitial fibrosis on biopsy is the single best histologic predictor of progression to dialysis.
• Heart. Post-infarct replacement fibrosis and the diffuse interstitial fibrosis of hypertensive and diabetic hearts stiffen the ventricle, causing diastolic heart failure and arrhythmia.
• Skin and systemic — scleroderma. Systemic sclerosis fibroses skin, lungs, and gut simultaneously; keloids are a localized dermal version of the same overshoot.
• Bone marrow — myelofibrosis. Megakaryocyte-driven cytokine release scars the marrow, displacing blood production.

Fibrosis versus regeneration

The fate of an injured organ comes down to a competition between two outcomes — true regeneration that restores function, and fibrosis that merely seals the defect. Which one wins depends on the cell type, the severity, and above all whether the injury is a single hit or a chronic drip.

Feature	Regeneration (true repair)	Fibrosis (scar repair)
End tissue	Functional parenchyma restored	Collagen scar, no organ-specific function
Dominant cell	Resident stem/progenitor cells dividing	Persistent myofibroblast (α-SMA+)
Matrix	Normal, organized, remodeled back to baseline	Excess type I collagen, lysyl-oxidase cross-linked
Typical trigger	Single, resolvable injury	Repeated or unresolved chronic injury
TGF-β signaling	Transient, then resolves	Sustained, self-amplifying
Mechanical result	Normal compliance restored	Marked stiffening (e.g. liver 2–6 → >12 kPa)
Reversibility	Complete	Partial early; near-irreversible once cross-linked

Slowing and reversing the scar

The first and most powerful antifibrotic intervention is to remove the driving injury. Curing hepatitis C with direct-acting antivirals can regress liver fibrosis and even early cirrhosis over years; stopping alcohol, controlling glucose and blood pressure, and removing the offending drug or dust all halt the engine. When the trigger cannot be removed, drugs that target the fibrotic machinery slow progression: pirfenidone and nintedanib reduce the rate of FVC decline in idiopathic pulmonary fibrosis, blunting TGF-beta and tyrosine-kinase growth-factor signaling respectively, though neither dissolves established scar. Active research targets the myofibroblast directly — inducing its apoptosis or reverting it to quiescence — and aims to tip the matrix balance back toward degradation by matrix metalloproteinases and to block lysyl-oxidase cross-linking before the scar becomes permanent. Once collagen is heavily cross-linked and architecture has collapsed, organ transplant is often the only remaining option.

This article is educational and is not medical advice. If you are concerned about fibrosis or a related condition, consult a qualified clinician.